My primary research focus is the investigation of epigenomic alterations in ovarian cancer, and the results of those epigenetic anomalies on the cancer cell transcriptome. I am studying the epigenetics of drug-resistant ovarian cancer. Specifically, I am examining two potential epigenetic therapies: a methylation inhibitor, zebularine, and a novel HDAC inhibitor, HDACI-42, for chemosensitization of resistant tumor cells. An additional research interest is the mechanism(s) responsible for aberrant DNA methylation that occurs during tumor progression.
